Objective:
NHF Chapters must develop, support, and sustain influential advocacy programs to protect and enhance access to health care for the bleeding disorders community.
Method:
NHF supports the…
FOR IMMEDIATE RELEASE
MEDIA CONTACT:
Ilana Ostrin
212-328-3769
iostrin@hemophilia.org
September 12, 2021 — New York City —The State of the Science Research Summit (SOS),…
In February 2021, the U.S. Food and Drug Administration (FDA) partially rescinded a supplemental Biologics License Application (BLA) that the agency had granted, in error, for the recombinant factor IX product BeneFIX® (Pfizer). The temporary…
Knowing the importance of including the consumers voice in the future of research, the National Hemophilia Foundation (NHF) partnered with the software healthcare analytics company; ArborMetrix, to develop a cloud-based platform; NHF’s Community…
From basic science to clinical care, our research programs focus on finding better treatments and improving care for all bleeding disorders.
Von Willebrand disease (VWD) is the most common inherited bleeding disorder known in humans, but there are numerous barriers to accurate and timely diagnosis. In January 2021, new evidence-based guidelines were released by the American Society of…
The inherited bleeding disorders (IBD) community has witnessed significant advances in recent years thanks to novel therapeutic advances and technologies and improved diagnostic proficiency.Yet important gaps persistent, particularly for those with…
The objective of this study is to assess the relationship between self-reported physical activity, treatment regimen, mental health, and pain in persons with hemophilia (PWH) enrolled in CVR. Read Abstract